Mostrar el registro sencillo del ítem
dc.contributor.author
Tabesh, Maryam
dc.contributor.author
Magliano, D. J.
dc.contributor.author
Tanamas, S. K.
dc.contributor.author
Surmont, F.
dc.contributor.author
Bahendeka, S.
dc.contributor.author
Chiang, C. E.
dc.contributor.author
Elgart, Jorge Federico
dc.contributor.author
Gagliardino, Juan Jose
dc.contributor.author
Kalra, Sanjay
dc.contributor.author
Krishnamoorthy, S.
dc.contributor.author
Luk, Andrea
dc.contributor.author
Maegawa, H.
dc.contributor.author
Motala, A. A.
dc.contributor.author
Pirie, F.
dc.contributor.author
Ramachandran, A.
dc.contributor.author
Tayeb, K.
dc.contributor.author
Vikulova, O.
dc.contributor.author
Wong, J.
dc.contributor.author
Shaw, J. E.
dc.date.available
2020-01-16T19:36:22Z
dc.date.issued
2019-07
dc.identifier.citation
Tabesh, Maryam; Magliano, D. J.; Tanamas, S. K.; Surmont, F.; Bahendeka, S.; et al.; Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015; Wiley Blackwell Publishing, Inc; Diabetic Medicine; 36; 7; 7-2019; 878-887
dc.identifier.issn
0742-3071
dc.identifier.uri
http://hdl.handle.net/11336/94950
dc.description.abstract
Aim: Optimal treatment of cardiovascular disease is essential to decrease mortality among people with diabetes, but information is limited on how actual treatment relates to guidelines. We analysed changes in therapeutic approaches to anti-hypertensive and lipid-lowering medications in people with Type 2 diabetes from 2006 and 2015. Methods: Summary data from clinical services in seven countries outside North America and Western Europe were collected for 39 684 people. Each site summarized individual-level data from outpatient medical records for 2006 and 2015. Data included: demographic information, blood pressure (BP), total cholesterol levels and percentage of people taking statins, anti-hypertensive medication (angiotensin-converting enzyme inhibitors, calcium channel blockers, angiotensin II receptor blockers, thiazide diuretics) and antiplatelet drugs. Results: From 2006 to 2015, mean cholesterol levels decreased in six of eight sites (range: −0.5 to −0.2), whereas the proportion with BP levels > 140/90 mmHg increased in seven of eight sites. Decreases in cholesterol paralleled increases in statin use (range: 3.1 to 47.0 percentage points). Overall, utilization of anti-hypertensive medication did not change. However, there was an increase in the use of angiotensin II receptor blockers and a decrease in angiotensin-converting enzyme inhibitors. The percentage of individuals receiving calcium channel blockers and aspirin remained unchanged. Conclusions: Our findings indicate that control of cholesterol levels improved and coincided with increased use of statins. The percentage of people with BP > 140/90 mmHg was higher in 2015 than in 2006. Hypertension treatment shifted from using angiotensin-converting enzyme inhibitors to angiotensin II receptor blockers. Despite the potentially greater tolerability of angiotensin II receptor blockers, there was no associated improvement in BP levels.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Wiley Blackwell Publishing, Inc
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc/2.5/ar/
dc.subject
cardiovascular
dc.subject
diabetes
dc.subject
North America
dc.subject
Western Europe
dc.subject.classification
Endocrinología y Metabolismo
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Cardiovascular disease management in people with diabetes outside North America and Western Europe in 2006 and 2015
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-10-15T14:48:46Z
dc.journal.volume
36
dc.journal.number
7
dc.journal.pagination
878-887
dc.journal.pais
Reino Unido
dc.journal.ciudad
Londres
dc.description.fil
Fil: Tabesh, M.. Monash University; Australia
dc.description.fil
Fil: Magliano, D.J.. Baker Heart And Diabetes Institute; Australia
dc.description.fil
Fil: Tanamas, S.K.. Baker Heart And Diabetes Institute; Australia
dc.description.fil
Fil: Surmont, F.. Monash University; Australia
dc.description.fil
Fil: Bahendeka, S.. Baker Heart And Diabetes Institute; Australia
dc.description.fil
Fil: Chiang, C.-E.. Astrazeneca;
dc.description.fil
Fil: ELGART, JORGE FEDERICO. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina
dc.description.fil
Fil: Gagliardino, Juan Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Centro de Endocrinología Experimental y Aplicada (i); Argentina
dc.description.fil
Fil: Kalra, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); Argentina
dc.description.fil
Fil: Krishnamoorthy, S.. Centro de Endocrinología Experimental y Aplicada (conicet- Universidad Nacional de la Plata); Argentina
dc.description.fil
Fil: Luk, A.. Bharti Hospital; India
dc.description.fil
Fil: Maegawa, H.. Dr. A Ramachandran's Diabetes Hospitals; India
dc.description.fil
Fil: Motala, A.A.. Prince Of Wales Hospital Hong Kong; Hong Kong
dc.description.fil
Fil: Pirie, F.. Shiga University Of Medical Science;
dc.description.fil
Fil: Ramachandran, A.. University Of Kwazulu-natal;
dc.description.fil
Fil: Tayeb, K.. University Of Kwazulu-natal;
dc.description.fil
Fil: Vikulova, O.. Dr. A Ramachandran's Diabetes Hospitals; India
dc.description.fil
Fil: Wong, J.. Al Noor Specialist Hospital;
dc.description.fil
Fil: Shaw, J.E.. Endocrinology Research Centre;
dc.journal.title
Diabetic Medicine
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1111/dme.13858
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1111/dme.13858
Archivos asociados